You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2-positive

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Her2-positive/Low-expression Urinary and Digestive Tract Tumors Trial in Beijing (BL-M07D1)

Not yet recruiting
  • Her2-positive/Low-expression Urinary and Digestive Tract Tumors
  • Beijing, Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Sep 8, 2023

Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab Trial in Guangzhou (Trastuzumab and

Recruiting
  • Early-stage Breast Cancer
  • +4 more
  • Trastuzumab and nelatinib
  • Trastuzumab and Parstuzumab
  • Guangzhou, China
    Sun Yat-sen University Sun Yat-sen Memorial Hospital
Mar 12, 2023

Breast Cancer Trial in Taizhou (Pyrotinib)

Recruiting
  • Breast Cancer
  • Taizhou, Zhejiang, China
    Taizhou Hospital
May 26, 2023

Breast Cancer Trial (Pyrotinib, Trastuzumab, Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Apr 22, 2023

t Pathologic Complete Response Observed in HER2 Positive Breast

Completed
  • HER2+ Breast Cancer
  • Rawalpindi, Punjab, Pakistan
    Rawalpindi Medical University
Jun 26, 2023

HER2-positive Breast Cancer Trial in Rome (PIK3CA analysis)

Active, not recruiting
  • HER2-positive Breast Cancer
  • PIK3CA analysis
  • Rome, RM, Italy
    Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Feb 20, 2023

HER-2 Positive Breast Cancer Trial in Tianjin (TCbHP VS ddEC-THP)

Recruiting
  • HER-2 Positive Breast Cancer
  • TCbHP VS ddEC-THP
  • Tianjin, Tianjin, China
    Breast Oncology, Tianjin Medical University Cancer Institute and
May 15, 2023

Triple Negative Breast Cancer, HER2-positive Breast Cancer Trial in Shanghai (proton plus carbon ion radiotherapy)

Recruiting
  • Triple Negative Breast Cancer
  • HER2-positive Breast Cancer
  • proton plus carbon ion radiotherapy
  • Shanghai, China
    Shanghai Proton and Heavy Ion center
Jan 11, 2023

HER2-positive Advanced Gastric Cancer Trial (trastuzumab, bevacizumab with paclitaxel (triple combination))

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer
  • trastuzumab, bevacizumab with paclitaxel (triple combination)
  • (no location specified)
Dec 6, 2022

HER2-PositiveRecurrent or Metastatic Breast Cancer Trial (SHR-A1811 Injection, SHR-A1811 Injection ; Pertuzumab Injection,

Not yet recruiting
  • HER2-PositiveRecurrent or Metastatic Breast Cancer
  • SHR-A1811 Injection
  • +2 more
  • (no location specified)
Sep 21, 2023

HER2-positive Recurrent/Metastatic Breast Cancer Trial (Inetetamab, pyrotinib, chemo)

Not yet recruiting
  • HER2-positive Recurrent/Metastatic Breast Cancer
  • Inetetamab, pyrotinib, chemotherapy
  • (no location specified)
Nov 16, 2022

HER2 Gene Mutation Trial in Shanghai (Injection of IAH0968+Gemcitabine+Cisplatin, Gemcitabine+Cisplatin)

Recruiting
  • HER2 Gene Mutation
  • Injection of IAH0968+Gemcitabine+Cisplatin
  • Gemcitabine+Cisplatin
  • Shanghai, China
    Fudan University Affiliated Zhongshan Hospital
Aug 7, 2023

Breast Cancer, Brain Metastases, Radiotherapy Trial in Shanghai (Combination use of SRT with T-DXd)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Combination use of SRT with T-DXd
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Oct 14, 2023

Advanced Gastric Carcinoma Trial in Dhaka (Trastuzumab, Oxaliplatin, Capecitabine)

Completed
  • Advanced Gastric Carcinoma
  • Dhaka, Bangladesh
    Bangabandhu Sheikh Mujib Medical University
Aug 15, 2023

Advanced/ Metastatic Her-2 Positive Breast Cancer Trial in Shanghai (GQ1001+pyrotinib, pyrotinib+capecitabine)

Active, not recruiting
  • Advanced/ Metastatic Her-2 Positive Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 15, 2022

HER2-positive Breast Cancer Trial in Amsterdam (Trastuzumab deruxtecan)

Not yet recruiting
  • HER2-positive Breast Cancer
  • Trastuzumab deruxtecan
  • Amsterdam, Netherlands
    Antoni van Leeuwenhoek
Aug 7, 2023

HER2-positive Breast Cancer Trial in Nanjing (HS022, Trastuzumab, Vinorelbine Bitartrate)

Completed
  • HER2-positive Breast Cancer
  • Nanjing, Jiangsu, China
    Jiangsu Province People's Hospital (First Affiliated Hospital of
Oct 25, 2023

Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer

Recruiting
  • Breast Cancer
  • Whole breast irradiation +/- tumor bed boost
  • Seoul, Korea, Republic of
    Samsung Medical Center
May 30, 2023

Breast Cancer Trial in Nanjing (Disitamb Vedotin ,pyrotinib)

Not yet recruiting
  • Breast Cancer
  • Disitamb Vedotin ,pyrotinib
  • Nanjing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Aug 18, 2023

T-Dxd in Treatment of HER2-positive BCBM After Prior Pyrotinib

Recruiting
  • Breast Cancer
  • Beijing, Beijing, China
  • +1 more
Nov 13, 2023

Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer

Not yet recruiting
  • HER2-positive Breast Cancer
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Sep 28, 2022

Metastatic Breast Cancer Trial (BDC-1001, Pertuzumab)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Jul 12, 2023

HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive NSCLC Trial (XMT-2056)

Not yet recruiting
  • HER2-positive Breast Cancer
  • +4 more
  • (no location specified)
Aug 23, 2022

HER2 Gene Mutation Trial (Injection of IAH0968 + CAPEOX, PLACEBO+CAPEOX)

Not yet recruiting
  • HER2 Gene Mutation
  • Injection of IAH0968 + CAPEOX
  • PLACEBO+CAPEOX
  • (no location specified)
Jan 4, 2023

Breast Cancer With Brain Metastases Trial in Wuhan (pyrotinib+capecitabine+bevacizumab)

Recruiting
  • Breast Cancer With Brain Metastases
  • Wuhan, Hubei, China
    Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 22, 2023